Depletion of T cell epitopes in lysostaphin mitigates anti-drug antibody response and enhances antibacterial efficacy in vivo.

[1]  Chris Bailey-Kellogg,et al.  Protein deimmunization via structure‐based design enables efficient epitope deletion at high mutational loads , 2015, Biotechnology and bioengineering.

[2]  Regina S. Salvat,et al.  Structure-based redesign of lysostaphin yields potent antistaphylococcal enzymes that evade immune cell surveillance , 2015, Molecular therapy. Methods & clinical development.

[3]  Chris Bailey-Kellogg,et al.  Structure‐based design of combinatorial mutagenesis libraries , 2015, Protein science : a publication of the Protein Society.

[4]  R. James,et al.  Crystal structure of the antimicrobial peptidase lysostaphin from Staphylococcus simulans , 2014, The FEBS journal.

[5]  David Baker,et al.  Removing T-cell epitopes with computational protein design , 2014, Proceedings of the National Academy of Sciences.

[6]  D. Baker,et al.  Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes , 2014, Proceedings of the National Academy of Sciences.

[7]  Chris Bailey-Kellogg,et al.  A high throughput MHC II binding assay for quantitative analysis of peptide epitopes. , 2014, Journal of visualized experiments : JoVE.

[8]  Chris Bailey-Kellogg,et al.  Gene and Protein Sequence Optimization for High-Level Production of Fully Active and Aglycosylated Lysostaphin in Pichia pastoris , 2014, Applied and Environmental Microbiology.

[9]  K. Griswold,et al.  A high‐throughput screen for antibiotic drug discovery , 2014, Biotechnology and bioengineering.

[10]  Saurabh Aggarwal,et al.  What's fueling the biotech engine—2012 to 2013 , 2014, Nature Biotechnology.

[11]  Vibha Jawa,et al.  T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation. , 2013, Clinical immunology.

[12]  Chris Bailey-Kellogg,et al.  Structure‐based redesign of proteins for minimal T‐cell epitope content , 2013, J. Comput. Chem..

[13]  Ronit Mazor,et al.  Identification and elimination of an immunodominant T-cell epitope in recombinant immunotoxins based on Pseudomonas exotoxin A , 2012, Proceedings of the National Academy of Sciences.

[14]  J. Cizeau,et al.  Preclinical evaluation of VB6-845: an anti-EpCAM immunotoxin with reduced immunogenic potential. , 2012, Cancer biotherapy & radiopharmaceuticals.

[15]  R. Kotłowski,et al.  Peptidoglycan hydrolases-potential weapons against Staphylococcus aureus , 2012, Applied Microbiology and Biotechnology.

[16]  Chris Bailey-Kellogg,et al.  Design and analysis of immune-evading enzymes for ADEPT therapy. , 2012, Protein engineering, design & selection : PEDS.

[17]  Dan S. Tawfik,et al.  Directed enzyme evolution: beyond the low-hanging fruit. , 2012, Current opinion in structural biology.

[18]  Chris Bailey-Kellogg,et al.  Structure-Guided Deimmunization of Therapeutic Proteins , 2012, RECOMB.

[19]  Chris Bailey-Kellogg,et al.  A divide‐and‐conquer approach to determine the Pareto frontier for optimization of protein engineering experiments , 2012, Proteins.

[20]  V. Fischetti,et al.  PEGylating a bacteriophage endolysin inhibits its bactericidal activity , 2011, AMB Express.

[21]  Chris Bailey-Kellogg,et al.  Optimization of Therapeutic proteins to Delete T-Cell epitopes while Maintaining Beneficial Residue Interactions , 2011, J. Bioinform. Comput. Biol..

[22]  F. Arnold,et al.  Optimizing non-natural protein function with directed evolution. , 2011, Current opinion in chemical biology.

[23]  George Georgiou,et al.  Therapeutic enzyme deimmunization by combinatorial T-cell epitope removal using neutral drift , 2011, Proceedings of the National Academy of Sciences.

[24]  Morten Nielsen,et al.  Peptide binding predictions for HLA DR, DP and DQ molecules , 2010, BMC Bioinformatics.

[25]  Yoonjoo Choi,et al.  FREAD revisited: Accurate loop structure prediction using a database search algorithm , 2010, Proteins.

[26]  R. Dubridge,et al.  The immunogenicity of humanized and fully human antibodies , 2010, mAbs.

[27]  Tim D. Jones,et al.  Prediction of Immunogenicity of Therapeutic Proteins , 2010, BioDrugs.

[28]  I. Pastan,et al.  Phase I Trial of Continuous Infusion Anti-Mesothelin Recombinant Immunotoxin SS1P , 2009, Clinical Cancer Research.

[29]  J. Cizeau,et al.  Engineering and Biological Characterization of VB6-845, an Anti-EpCAM Immunotoxin Containing a T-cell Epitope-depleted Variant of the Plant Toxin Bouganin , 2009, Journal of immunotherapy.

[30]  Gevorg Grigoryan,et al.  Design of protein-interaction specificity affords selective bZIP-binding peptides , 2009, Nature.

[31]  Amy C. Anderson,et al.  Computational structure-based redesign of enzyme activity , 2009, Proceedings of the National Academy of Sciences.

[32]  F. Niesen,et al.  The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability , 2007, Nature Protocols.

[33]  Bruce Tidor,et al.  Progress in computational protein design. , 2007, Current opinion in biotechnology.

[34]  V. Hornak,et al.  Comparison of multiple Amber force fields and development of improved protein backbone parameters , 2006, Proteins.

[35]  A. Sali,et al.  Statistical potential for assessment and prediction of protein structures , 2006, Protein science : a publication of the Protein Society.

[36]  Fei Zhou,et al.  Ultra-Fast Evaluation of Protein Energies Directly from Sequence , 2006, PLoS Comput. Biol..

[37]  M. Sugai,et al.  Cell Wall-targeting Domain of Glycylglycine Endopeptidase Distinguishes among Peptidoglycan Cross-bridges* , 2006, Journal of Biological Chemistry.

[38]  M. Bochtler,et al.  Crystal structures of active LytM. , 2005, Journal of molecular biology.

[39]  Wolfgang Aehle,et al.  A β-lactamase with reduced immunogenicity for the targeted delivery of chemotherapeutics using antibody-directed enzyme prodrug therapy , 2005, Molecular Cancer Therapeutics.

[40]  S. Larson,et al.  Pilot Trial of Unlabeled and Indium-111–Labeled Anti–Prostate-Specific Membrane Antigen Antibody J591 for Castrate Metastatic Prostate Cancer , 2005, Clinical Cancer Research.

[41]  S. G. Odintsov,et al.  Latent LytM at 1.3A resolution. , 2004, Journal of molecular biology.

[42]  S. Walsh,et al.  Improved Pharmacokinetics and Reduced Antibody Reactivity of Lysostaphin Conjugated to Polyethylene Glycol , 2003, Antimicrobial Agents and Chemotherapy.

[43]  Huub Schellekens,et al.  Immunogenicity of therapeutic proteins: clinical implications and future prospects. , 2002, Clinical therapeutics.

[44]  Marc De Maeyer,et al.  Elimination of a Human T-cell Region in Staphylokinase by T-cell Screening and Computer Modeling , 2002, Thrombosis and Haemostasis.

[45]  Gajendra P. S. Raghava,et al.  ProPred: prediction of HLA-DR binding sites , 2001, Bioinform..

[46]  T L Blundell,et al.  Crystal structures of NK1–heparin complexes reveal the basis for NK1 activity and enable engineering of potent agonists of the MET receptor , 2001, The EMBO journal.

[47]  A. Sali,et al.  Protein Structure Prediction and Structural Genomics , 2001, Science.

[48]  J. Richardson,et al.  The penultimate rotamer library , 2000, Proteins.

[49]  Thomas L. Madden,et al.  Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. , 1997, Nucleic acids research.

[50]  G. Jackowski,et al.  Removal of endotoxin from recombinant protein preparations. , 1997, Clinical Biochemistry.

[51]  F. Falcioni,et al.  HLA-DR4-IE chimeric class II transgenic, murine class II-deficient mice are susceptible to experimental allergic encephalomyelitis , 1996, The Journal of experimental medicine.

[52]  Peter A. Kollman,et al.  AMBER, a package of computer programs for applying molecular mechanics, normal mode analysis, molecular dynamics and free energy calculations to simulate the structural and energetic properties of molecules , 1995 .

[53]  W. C. Still,et al.  Semianalytical treatment of solvation for molecular mechanics and dynamics , 1990 .

[54]  M. Artenstein,et al.  Systemic lysostaphin in man--apparent antimicrobial activity in a neutropenic patient. , 1974, The New England journal of medicine.

[55]  P. Y. Chou,et al.  Prediction of protein conformation. , 1974, Biochemistry.

[56]  Pablo Gainza,et al.  Osprey: Protein Design with Ensembles, Flexibility, and Provable Algorithms , 2022 .

[57]  E. Mylonakis,et al.  Lysostaphin: a silver bullet for staph. , 2012 .

[58]  Narayanan Eswar,et al.  Protein structure modeling with MODELLER. , 2008, Methods in molecular biology.

[59]  Ira Mellman,et al.  Cell biology of antigen processing in vitro and in vivo. , 2005, Annual review of immunology.

[60]  E. Panosyan,et al.  Pharmacokinetic/Pharmacodynamic Relationships of Asparaginase Formulations , 2005, Clinical pharmacokinetics.

[61]  David Baker,et al.  Protein Structure Prediction Using Rosetta , 2004, Numerical Computer Methods, Part D.

[62]  G. Letchworth,et al.  High efficiency transformation by electroporation of Pichia pastoris pretreated with lithium acetate and dithiothreitol. , 2004, BioTechniques.

[63]  METHODOLOGY ARTICLE Methodology article Optimization algorithms for functional deimmunization of therapeutic proteins Open Access , 2022 .

[64]  J. Skolnick,et al.  Scoring function for automated assessment of protein structure template quality , 2004, Proteins.